Search in the Abstract Database

Abstracts Search 2014

* = Presenting author

P524. Crohn's disease localization does not contribute to response for induction therapy with infliximab in children

M. Dadalski, A. Wegner, J. Kierkus, Children's Memorial Health Institute, Gastroenterology, Hepatology and Feeding Disorders, Warsaw, Poland

Background

Induction therapy with infliximab is efficient in approximately 80% of children with Crohn's disease (CD). It's documented that male sex, concurrent immunomodulators, non-smoking behavior and luminal disease are the predictors of good infliximab response. It is questionable if ileal or colonic localization can contribute response for biological therapy. The aim of the study was to explore the contribution of CD gut localization to response for induction therapy with infliximab in children.

Methods

99 patients with PCDAI >30 pts and endoscopic evaluation (using Simple Endoscopic Score for Crohn's Disease (SES-CD), based on 4 endoscopic variables (ulcer size, ulcerated and affected surfaces, stenosis) in 5 ileocolonic segments (ileum, right colon, transverse colon, left colon, rectum) and the endoscopic parameters are scored from 0–3) performed were involved to the study and received induction therapy with infliximab 5 mg/kg at weeks 0, 2, and 6. Clinical (PCDAI score) response (decrease of PCDAI ≥15 AND PCDAI <30) and remission (PCDAI ≤10) were assessed at Week 10. Scorings in each ileocolonic segment were used as five independent variables in analysis of discrimination between: group with clinical response vs. no response and group with clinical remission vs. no remission.

Results

None of the analyzed variable had significant impact on discrimination between group with clinical response vs. no response - all partial Wilks' Lambda >0.99. The optimal model of discrimination had sensitivity 1.00 and specificity 0.00.

None of the analyzed variable had significant impact on discrimination between group with clinical remission vs. no remission - all partial Wilks' Lambda >0.99. The optimal model of discrimination had sensitivity 0.91 and specificity 0.08.

Conclusion

Crohn's disease localization does not contribute to response for induction therapy with infliximab in children.